IP Library Granted Patent US 12,479,841
Granted Patent B2
US 12,479,841 · App. 17/785,646 · Granted Nov 25, 2025

Anthelmintic compounds comprising azaindoles structure

Inventors: Michael Berger (Wiesbaden, DE); Michael R. Linder (Ingelheim, DE); Carolin Schneider (Hofheim, DE); Janina Tanzler (Nierder-Olm, DE); Ulrich Sondern (Dortmund, DE)
Assignee: Intervet, Inc.
C07D471/04A01N43/90A01P5/00A61P33/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,479,841
App. No.
17/785,646
Granted
Nov 25, 2025
Kind
B2
Abstract

The present invention relates to new anthelmintic compounds. These compounds can for example be used in the treatment of the kind of worm disease caused by helminths such as Dirofilaria , in particular Dirofilaria immitis.

Claims (119)

1 . Compound of Formula (I)

wherein

R 1 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, NR 2 R 3 , COOH, C(═O)OR 4 , SR 4 , SOR 4 , SO 2 R 4 , SO 2 NR 5 R 6 and C(═O)NR 5 R 6 ,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy or C 1-6 -alkylmercapto, is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, NR 2′ R 3′ , C(═O)OR 4′ , SR 4′ , SOR 4′ , SO 2 R 4′ , SO 2 NR 5′ R 6′ and C(═O)NR 5′ R 6′ ,

R 2 and R 3 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -alkyl substituted with C 3-10 -cycloalkyl, C 1-6 -alkyl substituted with 5- to 10-membered heterocyclyl, C 1-6 -alkyl substituted with C 6-10 -aryl and C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl, or

R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -alkyl substituted with C 3-10 -cycloalkyl, C 1-6 -alkyl substituted with 5- to 10-membered heterocyclyl, C 1-6 -alkyl substituted with C 6-10 -aryl or C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 2″ R 3″ , C(═O)OR 4″ , SR 4″ , SOR 4 , SO 2 R 4″ , SO 2 NR 5″ R 6″ and C(═O)NR 5″ R 6″ ,

R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6 -alkyl,

R 2′ , R 3′ , R 4′ , R 5′ and R 6′ are independently selected from hydrogen and C 1-6 -alkyl,

R 2″ , R 3″ , R 4″ , R 5″ and R 6″ are independently selected from hydrogen and C 1-6 -alkyl,

R 7 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 4- to 10-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, NR 8 R 9 , COOH, C(═O)OR 10 , SR 10 , SOR 10 SO 2 R 10 , SO 2 NR 11 R 12 and C(═O)NR 11 R 12 ,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 4- to 10-membered heterocyclyl, C 6-10 aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy or C 1-6 -alkylmercapto is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, NR 8′ R 9′ , C(═O)OR 10′ , SR 10′ , SOR 10′ , SO 2 R 10′ , SO 2 NR 11′ R 12′ and C(═O)NR 11′ R 12′ ,

R 8 and R 9 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -alkyl substituted with C 3-10 -cycloalkyl, C 1-6 -alkyl substituted with 5- to 10-membered heterocyclyl, C 1-6 -alkyl substituted with C 6-10 -aryl, and C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl, or

R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1-6 -alkyl substituted with C 3-10 -cycloalkyl, C 1-6 -alkyl substituted with 5- to 10-membered heterocyclyl, C 1-6 -alkyl substituted with C 6-10 -aryl or C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 8″ R 9″ , C(═O)OR 10″ , SR 10″ , SOR 10″ , SO 2 R 10″ , SO 2 NR 11″ R 12″ and C(═O)NR 11″ R 12″ ,

R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6 -alkyl,

R 8′ , R 9′ , R 10′ , R 11′ and R 12′ are independently selected from hydrogen and C 1-6 -alkyl,

R 8″ , R 9″ , R 10″ , R 11″ and R 12″ are independently selected from hydrogen and C 1-6 -alkyl,

R 13 is hydrogen or C 1-3 alkyl,

R 14 is hydrogen, C 1-3 alkyl, C 1-3 alkoxy, NR 14′ R 14″ , wherein R 14′ and R 14″ are independently C 1-3 -alkyl or

R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing non-aromatic ring, wherein the 5 or 6-carbon atoms containing ring is optionally substituted with one or more C 1-3 -alkyl or ═O, and/or wherein one or more of the ring forming carbon atoms are optionally replaced by —NH—, —N═, ═N—, —O—, —S(O)—, —S(O) 2 — or —S—, or R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing aromatic ring, wherein the 5 or 6-carbon atoms containing ring is optionally substituted with one or more C 1-3 -alkyl, and/or wherein one or more of the ring forming carbon atoms are optionally replaced by —NH—, —N═, ═N—, —O— or —S—,

R 15 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 15′ R 15″ , wherein R 15′ and R 15″ are independently C 1-3 -alkyl,

R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 16′ R 16″ , wherein R 16′ and R 16′ ″ are independently C 1-3 -alkyl,

R 17 is independently hydrogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 17′ R 17″ , wherein R 17′ and R 17″ are independently C 1-3 -alkyl,

R 18 is independently hydrogen, C 1-3 alkyl, C 1-3 alkoxy, or NR 18′ R 18″ , wherein R 18′ and R 18″ are independently C 1-3 -alkyl,

R 19 is independently selected from the group consisting of C 6-10 -aryl and 5- to 10-membered heteroaryl,

wherein each C 6-10 -aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, C 2-6 -alkenyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, C 1-6 -alkylmercapto, halogen, cyano, nitro, hydroxy, mercapto, NR 20 R 21 , C(═O)OR 22 , SR 22 , SOR 22 , SO 2 R 22 , SO 2 NR 23 R 24 and C(═O)NR 23 R 24 ,

R 20 and R 21 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1 -C 6 -alkyl substituted with C 6-10 -aryl, and C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl, or

R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy-C 1-6 -alkyl, C 1 -C 6 -alkyl substituted with C 6-10 -aryl, and C 1-6 -alkyl substituted with 5- to 10-membered heteroaryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of

C 1-6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, carbonyl, halogen, cyano, hydroxy, mercapto, NR 20′ R 21′ , C(═O)OR 22′ , SR 22′ , SOR 22′ , SO 2 R 22′ , SO 2 NR 23′ R 24′ , and C(═O)NR 23′ R 24′ ,

R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6 -alkyl,

R 20′ , R 21′ , R 22′ , R 23′ and R 24′ are independently selected from hydrogen and C 1-6 -alkyl,

R 25 is independently selected from hydrogen and C 1-6 -alkyl,

or a stereoisomer, physiologically acceptable salt, ester, solvate, polymorph or prodrug or a mixture thereof.

2 . The compound according to claim 1 , wherein R 1 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, nitro, hydroxy, NR 2 R 3 , C(═O)OR 4 and C(═O)NR 5 R 6 ,

wherein each C 1-6 -alkyl or C 1-6 -alkoxy is optionally substituted with one or more substituents independently selected from the group consisting of C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, nitro, hydroxy and NR 2′ R 3′ ,

R 2 and R 3 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl and 5 to 10-membered heteroaryl, or

R 2 and R 3 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2 or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl or 5 to 10-membered heteroaryl or the heterocyclic ring formed by R 2 and R 3 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 3-10 -cycloalkyl and C 1-6 -alkoxy,

R 4 , R 5 and R 6 are independently selected from hydrogen and C 1-6 -alkyl,

R 2′ and R 3′ are independently selected from hydrogen and C 1-6 -alkyl.

3 . The compound according to claim 1 , wherein R 1 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 1-6 -alkoxy and halogen,

wherein each C 1-6 -alkyl or C 1-6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, hydroxy and NR 2′ R 3′ ,

wherein R 2′ and R 3′ are independently selected from hydrogen and C 1-3 -alkyl.

4 . The compound according to claim 1 , wherein R 1 is independently selected from the group consisting of hydrogen, methyl, trifluoromethyl, ethyl, methoxy, ethoxy, fluoride and chloride.

5 . The compound according to claim 1 , wherein R 7 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, C 3-10 -cycloalkyl, 4- to 10 membered heterocyclyl, C 1-6 -alkoxy, halogen, cyano, hydroxy, NR 8 R 9 , C(═O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(═O)NR 11 R 12 ,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, C 3-10 -cycloalkyl, 4- to 10 membered heterocyclyl or C 1-6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, C 3-10 -cycloalkyl, 5- to 10 membered heterocyclyl, C 1-6 -alkoxy, halogen, cyano, hydroxy, NR 8′ R 9′ , C(═O)OR 10′ and C(═O)NR 11′ R 12′

R 8 and R 9 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl, 5- to 10 membered heterocyclyl and 5- to 10 membered heteroaryl, or

R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O,

wherein each C 1-6 -alkyl, C 3-10 -cycloalkyl, C 6-10 -aryl, 5- to 10 membered heterocyclyl, and 5- to 10 membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, hydroxy, NR 8″ R 9″ , C(═O)—OR 10″ and C(═O)NR 11″ R 12″ ,

R 10 , R 11 and R 12 are independently selected from hydrogen and C 1-6 -alkyl,

R 8′ , R 9′ , R 10′ , R 11′ and R 12′ are independently selected from hydrogen and C 1-6 -alkyl,

R 8″ , R 9″ , R 10″ , R 11″ and R 12″ are independently selected from hydrogen and C 1-6 -alkyl.

6 . The compound according to claim 1 , wherein R 7 is independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 2-6 -alkenyl, 4- to 10 membered heterocyclyl, C 1-6 -alkoxy, hydroxy, NR 8 R 9 , C(═O)OR 10 , SR 10 , SOR 10 , SO 2 R 10 and C(═O)NR 11 R 12 ,

wherein each C 1-6 -alkyl, C 2-6 -alkenyl, 4- to 10 membered heterocyclyl or C 1-6 -alkoxy is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, 5- to 10 membered heterocyclyl, C 1-6 -alkoxy, halogen, cyano, hydroxy, NR 8′ R 9′ , C(═O)OR 10′ and C(═O)NR 11′ R 12′ ,

R 8 and R 9 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 6-10 -aryl, and 5- to 10 membered heteroaryl, or

R 8 and R 9 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 1 ring atom is N and wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O;

wherein the C 1-6 -alkyl, C 6-10 -aryl, and 5- to 10 membered heteroaryl or the heterocyclic ring formed by R 8 and R 9 together with the N atom to which they are attached is optionally substituted with one or more substituent(s) independently selected from the group consisting of

C 1-6 -alkyl, C 1-6 -alkoxy, hydroxy and NR 8″ R 9″ ,

R 10 , R 11 and R 12 are independently selected from hydrogen or C 1-6 -alkyl,

R 8′ , R 9′ , R 10′ , R 11′ and R 12′ are independently selected from hydrogen or C 1-6 -alkyl,

R 8″ are R 9″ are independently selected from hydrogen or C 1-6 -alkyl.

7 . The compound according to claim 1 , wherein R 7 is independently selected from the group consisting of methyl, ethyl, isopropyl, ethenyl, 2-propenyl, methoxy, ethoxy, hydroxy, dimethylamino, and morpholin-4-yl.

8 . The compound according to claim 1 , wherein R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing non-aromatic ring, wherein the 5 or 6-carbon atoms containing ring is optionally substituted with one or more C 1-3 -alkyl or ═O, and/or wherein one or more of the ring forming carbon atoms are optionally replaced by —NH—, —N═, ═N—, —O—, —S(O)—, —S(O) 2 — or —S—,

R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15′ R 15″ , wherein R 15′ and R 15″ are independently C 1-3 -alkyl,

R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16′ R 16″ , wherein R 16′ and R 16″ are independently C 1-3 -alkyl,

R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

9 . The compound according to claim 1 , wherein R 13 and R 14 together with the atoms to which they are attached form a 5 or 6-carbon atoms containing aromatic ring, the 5 or 6-carbon atoms containing ring is optionally substituted with one or more C 1-3 -alkyl and/or wherein one or more of the ring forming carbon atoms are optionally replaced by —NH—, —N═, ═N—, —O— or —S—,

R 15 is independently hydrogen, halogen C 1-3 alkyl, C 1-3 alkoxy or NR 15′ R 15″ , wherein R 15′ and R 15″ are independently C 1-3 -alkyl,

R 16 is independently hydrogen, halogen, C 1-3 alkyl, C 1-3 alkoxy or NR 16′ R 16″ , wherein R 16′ and R 16″ are independently C 1-3 -alkyl,

R 17 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy,

R 18 is independently hydrogen, C 1-3 alkyl or C 1-3 alkoxy.

10 . The compound according to claim 1 , wherein R 19 is independently selected from the group consisting of

C 6-10 -aryl and 5- to 10-membered heteroaryl,

wherein each C 6-10 -aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, halogen, cyano, nitro, hydroxy, NR 20 R 21 , C(═O)OR 22 and C(═O)NR 23 R 24 ,

R 20 and R 21 are independently selected from the group consisting of

hydrogen, C 1-6 -alkyl, C 3-10 -cycloalkyl and C 6-10 -aryl or

R 20 and R 21 together with the N atom to which they are attached form a saturated or unsaturated heterocyclic ring having 3 to 12 ring atoms, wherein 0, 1, 2, or 3 further ring atoms are selected from N, S and O;

wherein each C 1-6 -alkyl, C 3-10 -cycloalkyl or C 6-10 -aryl or the heterocyclic ring formed by R 20 and R 21 together with the N atom to which they are attached is optionally substituted with one or more substituents independently selected from the group consisting of

C 1-6 -alkyl, C 3-10 -cycloalkyl, 5- to 10-membered heterocyclyl, C 6-10 -aryl, 5- to 10-membered heteroaryl, C 1-6 -alkoxy, halogen, cyano, hydroxy, NR 20′ R 21′ C(═O)OR 22′ and C(═O)NR 23′ R 24′ ,

R 22 , R 23 and R 24 are independently selected from hydrogen and C 1-6 -alkyl,

R 20′ , R 21′ , R 22′ , R 23′ and R 24′ are independently selected from hydrogen and C 1-6 -alkyl.

11 . The compound according to claim 1 , wherein R 19 is independently selected from the group consisting of

C 6-10 -aryl and 5- to 10-membered heteroaryl

wherein each C 6-10 -aryl or 5- to 10-membered heteroaryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, C 1-6 -alkoxy, halogen, cyano, nitro and hydroxy.

12 . The compound according to claim 1 , wherein R 19 is C 6-10 -aryl,

wherein the C 6-10 -aryl is optionally substituted with one or more substituent(s) independently selected from the group consisting of C 1-6 -alkyl, halogen, cyano and nitro.

13 . The compound according to claim 1 , wherein R 19 is C 6-10 -aryl,

wherein the C 6-10 -aryl is phenyl substituted with one, two or three substituents independently selected from the group consisting of fluoride, chloride and bromide.

14 . The compound according to claim 1 , wherein R 25 is hydrogen.

15 . The compound according to claim 1 being present in form of the (S)-enantiomer.

16 . A veterinary composition comprising

a compound according to Formula (I) according to claim 1 , and

one or more physiologically acceptable excipient(s).

17 . The veterinary composition according to claim 16 , wherein the one or more physiologically acceptable excipient(s) are selected from carriers, fillers, flavours, binders, antioxidants, buffers, sugar components, lubricants, surfactants, stabilizers, flow agents, disintegration agents and preservatives or a mixture thereof.

18 . A method of treating disorders/diseases caused by helminths comprising administering to an animal an effective amount of the compound of Formula (I) according to claim 1 .

19 . The method according to claim 18 , wherein the helminths are Dirofilaria immitis.

20 . A process for preparing the compound according to Formula (I) comprising the step of

reacting a compound of Formula (A)

with a compound of Formula (B)

Hal-R 19    Formula (B)

wherein Hal is a halogen and

R 1 , R 7 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 19 and R 25 are defined as in claim 1 , to obtain the compound according to Formula (I).

Assignments (4)
CHANGE OF ADDRESS Recorded Sep 26, 2023
From: INTERVET INC.
To: INTERVET INC.
Reel/Frame 065028/0818 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2022
From: BERGER, MICHAEL; LINDER, MICHAEL R.; SCHNEIDER, CAROLIN; TANZLER, JANINA; SONDERN, ULRICH
To: MSD ANIMAL HEALTH INNOVATION GMBH
Reel/Frame 060223/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2022
From: MSD ANIMAL HEALTH INNOVATION GMBH
To: INTERVET INTERNATIONAL B.V
Reel/Frame 060223/0615 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2022
From: INTERVET INTERNATIONAL B.V.
To: INTERVET INC.
Reel/Frame 060223/0700 →
Priority Claims (2)
EP 19217671 · Dec 18, 2019 · regional
EP 20213299 · Dec 11, 2020 · regional
Continuity (1)
Related Publication 20230110397A1 · Apr 13, 2023
References Cited (52)
US 5399582A · Endris et al. · 1995 [cited by applicant]
US 5595991A · Shoop et al. · 1997 [cited by applicant]
US 5834260A · Byrne et al. · 1998 [cited by applicant]
US 5945317A · Byrne et al. · 1999 [cited by applicant]
US 5962499A · Meinke et al. · 1999 [cited by applicant]
US 6221894B1 · Meinke et al. · 2001 [cited by applicant]
US 7312248B2 · Meyer et al. · 2007 [cited by applicant]
US 7361689B2 · Shuster et al. · 2008 [cited by applicant]
US 8106212B2 · Jeschke et al. · 2012 [cited by applicant]
US 20050182059A1 · Winzenberg et al. · 2005 [cited by applicant]
US 20060128779A1 · Winzenberg et al. · 2006 [cited by applicant]
US 20060281695A1 · Meyer et al. · 2006 [cited by applicant]
EP 0539588A1 · 1993 [cited by applicant]
WO 1996029073A1 · 1996 [cited by applicant]
WO 2002085838A1 · 2002 [cited by applicant]
WO 2007115643A1 · 2007 [cited by applicant]
WO 2010053517A2 · 2010 [cited by applicant]
WO 2010075591A2 · 2010 [cited by applicant]
WO 2012041873A1 · 2012 [cited by applicant]
WO 2017106607A1 · 2017 [cited by applicant]
WO 2017178416A1 · 2017 [cited by applicant]
WO 2017192385A1 · 2017 [cited by applicant]
WO 2018087036A1 · 2018 [cited by applicant]
WO 2018197401A1 · 2018 [cited by applicant]
WO 2019002132A1 · 2019 [cited by applicant]
WO 2019170626A1 · 2019 [cited by applicant]
WO 2019197468A1 · 2019 [cited by applicant]
WO 2019201835A1 · 2019 [cited by applicant]
WO 2019206799A1 · 2019 [cited by applicant]
WO 2019215198A1 · 2019 [cited by applicant]
WO 2020053364A1 · 2020 [cited by applicant]
WO 2020053365A2 · 2020 [cited by applicant]
WO 2020070049A1 · 2020 [cited by applicant]
WO 2020079198A1 · 2020 [cited by applicant]
WO 2020094363A1 · 2020 [cited by applicant]
WO WO2020087170A1 · 2020 [cited by examiner]
WO 2020169445A1 · 2020 [cited by applicant]
WO 2020193341A1 · 2020 [cited by applicant]
WO 2020201079A1 · 2020 [cited by applicant]
WO 2020201398A1 · 2020 [cited by applicant]
WO 2020208036A1 · 2020 [cited by applicant]
WO 2020212235A1 · 2020 [cited by applicant]
WO 2020219871A1 · 2020 [cited by applicant]
El-Faham, Ayman et al., Peptide Coupling Reagents, More than a Letter Soup, Chemical Reviews, 2011, 6557-6602, 111. [cited by applicant]
Kokatla, Hari Prasad et al., Structure-Based Design of Novel Human Toll-like Receptor 8 Agonists, ChemMedChem, 2014, 719-723, 9. [cited by applicant]
Liddle, John et al., 4-Phenyl-7-azaindoles as potent, selective and bioavailable IKK2 inhibitors demonstrating good in vivo efficacy, Bioorg. Med. Chem. Lett., 2012, 5222-5226, 22. [cited by applicant]
Nakajima, Yutaka et al., Synthesis and Evaluation of 1H-Pyrrolo[2,3-b]pyridine Derivatives as Novel Immunomodulators Targeting Janus Kinase 3, Chem. Pharm. Bull., 2015, 341-353, 63(5). [cited by applicant]
Belikov, V.G., Pharmaceutical Chemistry, Moscow MEDpress-inform, 4th Edition, 27-29, 2007, English translation. [cited by applicant]
Bernstein, J., Bioavailability, Polymorphism of molecular crystals, Ch. 7.3.2, 324-330 (translated pp. 1-9), 2007, English translation. [cited by applicant]
Dyson, G. and May, P., Chemistry of Synthetic Medicinal Substances, M: World, N/A, 12-19, 1964, English translation. [cited by applicant]
Kummerer, K., Pharmaceuticals in the environment, Annual Review of Environment and Resources, 35, 57-75, 2010. [cited by applicant]
Pinto M.A.L. et al., Thermoanalytical studies of carbamazepine: hydration/dehydration, thermal decomposition, and solid phase transitions, Brazilian Journal of Pharmaceutical Sciences, 50, 877-884 (English abstract), 20… [cited by applicant]